Leaps by Bayer led a round that also featured Amgen Ventures, Intel Capital and Alexandria Ventures Investments, taking the gene therapy technology developer's total funding to $158m.

IP Group portfolio company Hinge Health has pushed its valuation to $3bn following a $300m series D round co-led by Coatue Management and Tiger Global.

Existing investor Pasteur Mutualité came back for a round that will precede a trial of Volta's software, which helps in the treatment of cardiac arrythmias.

The antibody drug developer, majority owned by Luye Pharma, pushed its valuation past $850m in a round backed by Bank of China’s BOCG vehicle.

Eli Lilly invested directly and through its Lilly Asia Ventures fund, in a round that brought liver disease-focused drug developer Terns' overall funding to $197m.

The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Utec has made its largest initial commitment to date by backing Keio-founded Metcela, a developer of cell therapies for heart disease.

SK Biopharmaceuticals will divest a 12% stake in Arvelle, which is looking to commercialise an epilepsy drug treatment, through the acquisition.

Bristol Myers Squibb participated in a series B round for the oncology drug developer that pushed its overall funding to $168m.